Open Studies but not enrolling
Sanofi Freviva The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis. Inclusion Criteria: 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years, without clinical […]
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
